Those aspiring to outpace the market meticulously engage in the process of selecting individual stocks. Strategic choices can be instrumental in accelerating your wealth.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
After finishing at $60.66 in the prior trading day, Catalent Inc. (NYSE: CTLT) closed at $60.28, down -0.63%. In other words, the price has decreased by -$0.63 from its previous closing price. On the day, 1.45 million shares were traded. CTLT stock price reached its highest trading level at $60.65 during the session, while it also had its lowest trading level at $60.24.
Ratios:
Our goal is to gain a better understanding of CTLT by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 1.96 and its Current Ratio is at 2.52. In the meantime, Its Debt-to-Equity ratio is 1.38 whereas as Long-Term Debt/Eq ratio is at 1.37.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Robert W. Baird on November 16, 2023, Upgraded its rating to Outperform and sets its target price to $53 from $45 previously.
On September 05, 2023, Argus Upgraded its rating to Buy which previously was Hold but kept the price unchanged to $62.
On July 20, 2023, Wells Fargo started tracking the stock assigning a Equal Weight rating and target price of $43.Wells Fargo initiated its Equal Weight rating on July 20, 2023, with a $43 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Oct 16 ’24 when Hawkeswood Thomas W bought 625 shares for $60.57 per share.
McErlane David sold 1,994 shares of CTLT for $119,580 on Sep 26 ’24. The Group President, Biologics now owns 36,304 shares after completing the transaction at $59.97 per share. On Sep 26 ’24, another insider, McErlane David, who serves as the Officer of the company, bought 2,168 shares for $59.98 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CTLT now has a Market Capitalization of 10938649600 and an Enterprise Value of 15636724736. For the stock, the TTM Price-to-Sale (P/S) ratio is 2.50 while its Price-to-Book (P/B) ratio in mrq is 3.03. Its current Enterprise Value per Revenue stands at 3.569 whereas that against EBITDA is 31.589.
Stock Price History:
Over the past 52 weeks, CTLT has reached a high of $61.20, while it has fallen to a 52-week low of $31.80. The 50-Day Moving Average of the stock is 0.34%, while the 200-Day Moving Average is calculated to be 6.39%.
Shares Statistics:
The stock has traded on average 1.75M shares per day over the past 3-months and 1263110 shares per day over the last 10 days, according to various share statistics. A total of 181.00M shares are outstanding, with a floating share count of 177.91M. Insiders hold about 1.96% of the company’s shares, while institutions hold 91.74% stake in the company. Shares short for CTLT as of 1727654400 were 8310488 with a Short Ratio of 4.75, compared to 1724976000 on 9120465. Therefore, it implies a Short% of Shares Outstanding of 8310488 and a Short% of Float of 5.8500000000000005.
